Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Clinical trial NCT05134441 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05134441
- Sponsor
- Immunic AG
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-18
- Primary completion
- 2026-11-01
- Enrollment
- 1121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.